293 related articles for article (PubMed ID: 30657975)
1. Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
Nishikawa MM; Almeida-Paes R; Brito-Santos F; Nascimento CR; Fialho MM; Trilles L; Morales BP; da Silva SA; Santos W; Santos LO; Fortes ST; Cardarelli-Leite P; Lázera MDS
Med Mycol; 2019 Oct; 57(7):864-873. PubMed ID: 30657975
[TBL] [Abstract][Full Text] [Related]
2. Reduced Susceptibility to Azoles in Cryptococcus gattii Correlates with the Substitution R258L in a Substrate Recognition Site of the Lanosterol 14-α-Demethylase.
Carvajal SK; Melendres J; Escandón P; Firacative C
Microbiol Spectr; 2023 Aug; 11(4):e0140323. PubMed ID: 37341584
[TBL] [Abstract][Full Text] [Related]
3. Multi-centre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. BSAC Working Party on Antifungal Chemotherapy.
Warnock DW; Johnson EM; Rogers TR
J Antimicrob Chemother; 1998 Sep; 42(3):321-31. PubMed ID: 9786472
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the Etest and microdilution method for antifungal susceptibility testing of Cryptococcus neoformans to four antifungal agents.
Aller AI; Martín-Mazuelos E; Gutiérrez MJ; Bernal S; Chávez M; Recio FJ
J Antimicrob Chemother; 2000 Dec; 46(6):997-1000. PubMed ID: 11102421
[TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of Etest and broth microdilution method (AFST-EUCAST) for trends in antifungal drug susceptibility testing of Brazilian Cryptococcus neoformans isolates.
Dias ALT; Matsumoto FE; Melhem MSC; da Silva EG; Auler ME; de Siqueira AM; Paula CR
J Med Microbiol; 2006 Dec; 55(Pt 12):1693-1699. PubMed ID: 17108273
[TBL] [Abstract][Full Text] [Related]
6. Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goiânia city, Goiás, Brazil.
Souza LK; Fernandes Ode F; Kobayashi CC; Passos XS; Costa CR; Lemos JA; Souza-Júnior AH; Silva Mdo R
Rev Inst Med Trop Sao Paulo; 2005; 47(5):253-6. PubMed ID: 16302107
[TBL] [Abstract][Full Text] [Related]
7. In vitro susceptibility of Cryptococcus gattii clinical isolates.
Gomez-Lopez A; Zaragoza O; Dos Anjos Martins M; Melhem MC; Rodriguez-Tudela JL; Cuenca-Estrella M
Clin Microbiol Infect; 2008 Jul; 14(7):727-30. PubMed ID: 18558948
[TBL] [Abstract][Full Text] [Related]
8. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
Tay ST; Tanty Haryanty T; Ng KP; Rohani MY; Hamimah H
Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448
[TBL] [Abstract][Full Text] [Related]
9. Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis.
Dannaoui E; Abdul M; Arpin M; Michel-Nguyen A; Piens MA; Favel A; Lortholary O; Dromer F;
Antimicrob Agents Chemother; 2006 Jul; 50(7):2464-70. PubMed ID: 16801427
[TBL] [Abstract][Full Text] [Related]
10. Molecular epidemiology and antifungal susceptibilities of Cryptococcus species isolates from HIV and non-HIV patients in Southwest China.
Wu SY; Kang M; Liu Y; Chen ZX; Xiao YL; He C; Ma Y
Eur J Clin Microbiol Infect Dis; 2021 Feb; 40(2):287-295. PubMed ID: 32895755
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Etest method for determining voriconazole and amphotericin B MICs for 162 clinical isolates of Cryptococcus neoformans.
Maxwell MJ; Messer SA; Hollis RJ; Diekema DJ; Pfaller MA
J Clin Microbiol; 2003 Jan; 41(1):97-9. PubMed ID: 12517832
[TBL] [Abstract][Full Text] [Related]
12. Antifungal susceptibility of Cryptococcus neoformans and Cryptococcus gattii isolates from decayed wood of trunk hollows of Ficus religiosa and Syzygium cumini trees in north-western India.
Khan ZU; Randhawa HS; Kowshik T; Chowdhary A; Chandy R
J Antimicrob Chemother; 2007 Aug; 60(2):312-6. PubMed ID: 17553813
[TBL] [Abstract][Full Text] [Related]
13. Correlation of antifungal susceptibility and sequence types within Cryptococcus neoformans VNI from HIV patients, and ERG11 gene polymorphism.
Bive BZ; Sacheli R; Mudogo CN; Zakayi PK; Bontems S; Lelo GM; Hayette MP
J Mycol Med; 2023 Nov; 33(4):101428. PubMed ID: 37651769
[TBL] [Abstract][Full Text] [Related]
14. Antifungal susceptibility of clinical and environmental isolates of Cryptococcus neoformans to four antifungal drugs determined by two techniques.
Moraes EM; Prímola NS; Hamdan JS
Mycoses; 2003 Jun; 46(5-6):164-8. PubMed ID: 12801356
[TBL] [Abstract][Full Text] [Related]
15. Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans.
Perkins A; Gomez-Lopez A; Mellado E; Rodriguez-Tudela JL; Cuenca-Estrella M
J Antimicrob Chemother; 2005 Dec; 56(6):1144-7. PubMed ID: 16282208
[TBL] [Abstract][Full Text] [Related]
16. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998.
Brandt ME; Pfaller MA; Hajjeh RA; Hamill RJ; Pappas PG; Reingold AL; Rimland D; Warnock DW;
Antimicrob Agents Chemother; 2001 Nov; 45(11):3065-9. PubMed ID: 11600357
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the relationship between drug susceptibility of Cryptococcus neoformans isolates and mortality in HIV-negative cryptococcal meningitis.
Su Z; Wei H; Liu J; Li C; Xu Z; Yuan D; Dai K; Peng F; Jiang Y
J Glob Antimicrob Resist; 2024 Mar; 36():167-174. PubMed ID: 38141953
[TBL] [Abstract][Full Text] [Related]
18. [Susceptibility to antifungal agents among Cryptococcus neoformans varieties isolated from patients at a university hospital].
Silva PR; Rabelo RA; Terra AP; Teixeira DN
Rev Soc Bras Med Trop; 2008; 41(2):158-62. PubMed ID: 18545836
[TBL] [Abstract][Full Text] [Related]
19. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
[TBL] [Abstract][Full Text] [Related]
20. Correlation of Neo-Sensitabs tablet diffusion assay results on three different agar media with CLSI broth microdilution M27-A2 and disk diffusion M44-A results for testing susceptibilities of Candida spp. and Cryptococcus neoformans to amphotericin B, caspofungin, fluconazole, itraconazole, and voriconazole.
Espinel-Ingroff A; Canton E; Gibbs D; Wang A
J Clin Microbiol; 2007 Mar; 45(3):858-64. PubMed ID: 17215342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
